Aedifica NV (AED) Fair Value & Analysis
Real Estate · BE · Market cap €5.8B
Fair value as of: Jul 17, 2026
From 13 valuation models · updated 23 days ago
Share price +0.1% over the past month.
A solid business, but screening 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€48.14). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (€21.82 to €48.14) leaves room in how you read the outcome.
- As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range €40.05 – €93.11 · fair‑value band €21.82 – €48.14 · the €69.25 price screens above the €36.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Aedifica NV (AED) currently trades at €69.25, while our model-based Fair Value estimate is €36.17, implying the stock looks roughly 47.8% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Trailing-twelve-month revenue stands at €391M. Revenue grew 23.4% year over year. It earns a return on equity of 11.1%. Net debt stands at €2.5B. Fundamentals as of Jul 17, 2026
Our scenario range runs from €21.82 (bear case) to €48.14 (bull case); at €69.25, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 23% above its 52-week low, currently above its 200-day average. For context, the median of 10 Real Estate peers we cover trades at -53% fair-value upside, at -48%, AED screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Growth DCF (€61.44) versus Asset-Based (€29.41). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aedifica NV/SA is a Belgian public regulated real estate company specializing in European healthcare real estate, particularly properties for elderly care. Aedifica has built a real estate portfolio worth approximately 12.4 billion euros in Belgium, Germany, the Netherlands, the United Kingdom, Finland, Ireland, Spain, France, and Italy.
Full company description
Aedifica NV/SA is a Belgian public regulated real estate company specializing in European healthcare real estate, particularly properties for elderly care. Aedifica has built a real estate portfolio worth approximately 12.4 billion euros in Belgium, Germany, the Netherlands, the United Kingdom, Finland, Ireland, Spain, France, and Italy. Aedifica is listed on Euronext Brussels (2006) and Euronext Amsterdam (2019) and is identified by the following codes: AED; AED:BB (Bloomberg); AOO.BR (Reuters). Since 2020, Aedifica has been a constituent of the BEL 20, the main stock market index of Euronext Brussels. Furthermore, since 2023, Aedifica has been included in the BEL ESG, the index that tracks the best-performing companies based on ESG criteria. Aedifica is also included in the EPRA, Stoxx Europe 600, and GPR indices. Its market capitalization was approximately 5.7 billion euros as of May 18th, 2026. Aedifica NV/SA was established on November 07, 2005 and incorporated in 2005 in Belgium.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aedifica NV reported revenue of €370M in FY2025 versus €231M in FY2021, a compound +12.5%/yr. Reported net income was €244M in FY2025, compounding −3.5%/yr from FY2021.
AED screens 48% overvalued. Compare with Welltower Inc →
Peer Group
REIT - Healthcare Facilities · 28 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs REIT - Healthcare Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more REIT - Healthcare Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Welltower Inc WELL | $231.59 | $42.21 | -82% |
| Ventas, Inc VTR | $100.53 | $18.07 | -82% |
| Omega Healthcare Investors, Inc OHI | $51.72 | $33.69 | -35% |
| Healthpeak Properties, Inc DOC | $22.27 | $7.02 | -68% |
| American Healthcare REIT, Inc AHR | $56.38 | $11.04 | -80% |
| CareTrust REIT, Inc CTRE | $43.25 | $23.07 | -47% |
| Healthcare Realty Trust Incorporated HR | $21.40 | $20.60 | -4% |
| Chartwell Retirement Residences CSHUN | C$22.81 | C$3.52 | -85% |
| Sabra Health Care REIT, Inc SBRA | $22.36 | $10.49 | -53% |
| National Health Investors, Inc NHI | $80.54 | $49.86 | -38% |
Compare Aedifica NV with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Real Estate stocks →
Frequently asked questions
Is Aedifica NV (AED) overvalued or undervalued?
What is the fair value of AED?
What is the quality score of AED?
What is the revenue of Aedifica NV (AED)?
What is the net profit margin of AED?
Does Aedifica NV pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aedifica NV and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.